1. Home
  2. CUE vs IROH Comparison

CUE vs IROH Comparison

Compare CUE & IROH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • IROH
  • Stock Information
  • Founded
  • CUE 2014
  • IROH 2021
  • Country
  • CUE United States
  • IROH United States
  • Employees
  • CUE N/A
  • IROH N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • IROH
  • Sector
  • CUE Health Care
  • IROH
  • Exchange
  • CUE Nasdaq
  • IROH Nasdaq
  • Market Cap
  • CUE 91.9M
  • IROH 91.2M
  • IPO Year
  • CUE 2018
  • IROH 2023
  • Fundamental
  • Price
  • CUE $1.26
  • IROH $10.38
  • Analyst Decision
  • CUE Strong Buy
  • IROH
  • Analyst Count
  • CUE 5
  • IROH 0
  • Target Price
  • CUE $5.00
  • IROH N/A
  • AVG Volume (30 Days)
  • CUE 285.1K
  • IROH 44.0K
  • Earning Date
  • CUE 03-10-2025
  • IROH 01-01-0001
  • Dividend Yield
  • CUE N/A
  • IROH N/A
  • EPS Growth
  • CUE N/A
  • IROH N/A
  • EPS
  • CUE N/A
  • IROH 0.20
  • Revenue
  • CUE $9,532,000.00
  • IROH N/A
  • Revenue This Year
  • CUE $73.11
  • IROH N/A
  • Revenue Next Year
  • CUE $11.02
  • IROH N/A
  • P/E Ratio
  • CUE N/A
  • IROH $53.07
  • Revenue Growth
  • CUE 149.53
  • IROH N/A
  • 52 Week Low
  • CUE $0.45
  • IROH $9.97
  • 52 Week High
  • CUE $2.58
  • IROH $11.11
  • Technical
  • Relative Strength Index (RSI)
  • CUE 49.50
  • IROH N/A
  • Support Level
  • CUE $1.27
  • IROH N/A
  • Resistance Level
  • CUE $1.50
  • IROH N/A
  • Average True Range (ATR)
  • CUE 0.12
  • IROH 0.00
  • MACD
  • CUE -0.01
  • IROH 0.00
  • Stochastic Oscillator
  • CUE 53.73
  • IROH 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About IROH Iron Horse Acquisitions Corp. Common Stock

Iron Horse Acquisitions Corp is a blank check company.

Share on Social Networks: